KT Corp (030200) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
KT Corp (KT) is a provider of telecommunication and internet services. The company’s service portfolio includes fixed-line and voice-over internet protocol (VoIP) telephone services, data communication, broadband internet access services, internet protocol television (IPTV), leased lines, satellite television, network services, information technology, and financial services. It also offers media and content services such as digital music services, e-commerce, online advertising consulting services, webcomics, and novels, cloud computing, and other data communication services. The company provides credit card processing and real estate services. It has a geographic presence in Hong Kong, Bangladesh, Vietnam, Botswana, the Philippines, Japan, South Korea, Thailand and the US. KT is headquartered in Seongnam City, GyeongGi-Do, South Korea.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Hanmi Pharmaceuticals Co Ltd - Key Facts
Hanmi Pharmaceuticals Co Ltd - Key Employees
Hanmi Pharmaceuticals Co Ltd - Key Employee Biographies
Hanmi Pharmaceuticals Co Ltd - Major Products and Services
Hanmi Pharmaceuticals Co Ltd - History
Hanmi Pharmaceuticals Co Ltd - Company Statement
Hanmi Pharmaceuticals Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Hanmi Pharmaceuticals Co Ltd - Business Description
Business Segment: Drug Substance
Overview
Performance
Business Segment: Medicine
Overview
Performance
Business Segment: Overseas Medicines
Overview
Performance
Geographical Segment: China
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: Republic of Korea
Performance
Geographical Segment: USA
Performance
R&D Overview
Hanmi Pharmaceuticals Co Ltd - Corporate Strategy
Hanmi Pharmaceuticals Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Hanmi Pharmaceuticals Co Ltd - Strengths
Hanmi Pharmaceuticals Co Ltd - Weaknesses
Hanmi Pharmaceuticals Co Ltd - Opportunities
Hanmi Pharmaceuticals Co Ltd - Threats
Hanmi Pharmaceuticals Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Hanmi Pharmaceuticals Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
Jun 01, 2026: Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide
May 27, 2026: Hanmi to Unveil Second Muscle-Building Obesity Candidate at ADA 2026
May 21, 2026: Hanmi Pharmaceutical Partners With Organon to Supply Combination Therapies in Southeast Asia
May 21, 2026: Hanmi Pharmaceutical Partners With Organon to Export Combination Therapies to Southeast Asia
Apr 28, 2026: Hanmi Showcases Next Generation Drug Innovations at AACR
Apr 06, 2026: Hanmi Records Highest Number of AACR Presentations Among Korean Biopharmas
Feb 05, 2026: Hanmi Pharmaceutical Delivers Record Results as Revenue Reaches USD 1.15 Billion
Dec 19, 2025: Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders To Approve the Acquisition by Hanmi Pending Final Clearance From SEC
Dec 11, 2025: The Clinical Utility of Amoprel and Rosuzet, the Two Leading Korean and Us Drugs, Has Been Confirmed
Nov 04, 2025: Hanmi Pharmaceutical distributes and sells three types of Boehringer Ingelheim COPD treatment in Korea
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Hanmi Pharmaceuticals Co Ltd, Key Facts
Hanmi Pharmaceuticals Co Ltd, Key Employees
Hanmi Pharmaceuticals Co Ltd, Key Employee Biographies
Hanmi Pharmaceuticals Co Ltd, Major Products and Services
Hanmi Pharmaceuticals Co Ltd, History
Hanmi Pharmaceuticals Co Ltd, Other Locations
Hanmi Pharmaceuticals Co Ltd, Subsidiaries
Hanmi Pharmaceuticals Co Ltd, Key Competitors
Hanmi Pharmaceuticals Co Ltd, Ratios based on current share price
Hanmi Pharmaceuticals Co Ltd, Annual Ratios
Hanmi Pharmaceuticals Co Ltd, Interim Ratios
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Hanmi Pharmaceuticals Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Hanmi Pharmaceuticals Co Ltd, Performance Chart (2021 - 2025)
Hanmi Pharmaceuticals Co Ltd, Ratio Charts
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net